Related Articles
Carbohydrate antigen 19‑9 as a prognostic biomarker in pancreatic neuroendocrine tumors
Patients with normal‑range CA19‑9 levels represent a distinct subgroup of pancreatic cancer patients
Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas
Pancreatic cyst fluid analysis for differential diagnosis between benign and malignant lesions
Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer